Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA HPV cancer vaccine
- Development stage
- Preclinical
- Lead developer
- LEVATIO Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
The mRNA HPV cancer vaccine is an investigational immunotherapy being developed by LEVATIO Therapeutics, a subsidiary of ST Pharm. This vaccine utilizes messenger RNA (mRNA) technology to deliver genetic instructions for the expression of Human Papillomavirus (HPV) E6 and E7 oncoproteins. These proteins are critical for the maintenance of the malignant phenotype in HPV-associated cancers, such as cervical cancer and certain head and neck cancers. By expressing these antigens in vivo, the vaccine is designed to prime the host's immune system, particularly cytotoxic T lymphocytes, to recognize and destroy HPV-positive tumor cells. The program is currently in the preclinical stage of development and leverages LEVATIO's expertise in both linear and circular mRNA (cmRNA) platforms.
- Other names
- mRNA HPV Cancer Vaccine
02
Targets
HPV16 E6 oncoproteinHuman papillomavirus type 18 protein E7 (HPV18 E7)HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on mRNA HPV cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA HPV cancer vaccine.